- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/64 - Relaxins
Patent holdings for IPC class C07K 14/64
Total number of patents in this class: 119
10-year publication summary
|
8
|
10
|
11
|
15
|
7
|
11
|
8
|
12
|
10
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ambrx, Inc. | 192 |
14 |
| Bristol-myers Squibb Company | 4863 |
10 |
| MedImmune Limited | 622 |
9 |
| Sanofi | 3951 |
9 |
| The Scripps Research Institute | 1353 |
8 |
| Immatics Biotechnologies GmbH | 1170 |
5 |
| Modernatx, Inc. | 1206 |
5 |
| Chemical & Biopharmaceutical Laboratories of Patras S.A. | 28 |
4 |
| Florey Institute of Neuroscience and Mental Health | 45 |
4 |
| Howard Florey Institute of Experimental Physiology and Medicine | 19 |
4 |
| Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | 6 |
4 |
| Tectonic Therapeutic, Inc. | 6 |
4 |
| Eli Lilly and Company | 3720 |
3 |
| River 2 Renal Corp. | 3 |
3 |
| Bayer Intellectual Property GmbH | 2569 |
2 |
| Adaptimmune Limited | 177 |
2 |
| National University of Singapore | 2369 |
2 |
| The University of Queensland | 657 |
2 |
| F. Hoffmann-La Roche AG | 7942 |
1 |
| AstraZeneca AB | 2958 |
1 |
| Other owners | 23 |